Characterization of genotypic and phenotypic changes in HIV-1-infected patients with virologic failure on an etravirine-containing regimen in the DUET-1 and DUET-2 clinical studies

AIDS Research and Human Retroviruses

Volumn 26, Issue 11, 2010, Pages 1197-1205

  Tambuyzer, Lotke ^a   Vingerhoets, Johan ^a   Azijn, Hilde ^a   Daems, Bjorn ^a   Nijs, Steven ^a   Béthune, Marie Pierre De ^a   Picchio, Gastón ^b  

^a TIBOTEC BVBA   (Belgium)

^b Tibotec Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DARUNAVIR PLUS RITONAVIR; ENFUVIRTIDE; ETRAVIRINE; PLACEBO; RNA DIRECTED DNA POLYMERASE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MUTATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REBOUND; VIRUS RESISTANCE;

AMINO ACID SUBSTITUTION; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG RESISTANCE, VIRAL; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION, MISSENSE; PEPTIDE FRAGMENTS; PYRIDAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RITONAVIR; SEQUENCE ANALYSIS, DNA; SULFONAMIDES; TREATMENT FAILURE; VIRAL LOAD;

EID: 78649305180     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0302     Document Type: Article

References (32)

1. Andries K, Azijn H, Thielemans T, et al.: Etravirine, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004;48:4680-4686.
2. Das K, Clark AD Jr, Lewi PJ, et al.: Roles of conformational and positional adaptability in structure-based design of etravirine-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem 2004;47:2550-2560.
3. Vingerhoets J, Azijn H, Fransen E, et al.: Etravirine displays a high genetic barrier to the development of resistance: Evidence from in vitro selection experiments. J Virol 2005;79:12773-12782.
4. Delaugerre C, Rohban R, Simon A, et al.: Resistance profile and cross-resistance of HIV-1 among patients failing a nonnucleoside reverse transcriptase inhibitor-containing regimen. J Med Virol 2001;65:445-448.
5. Bacheler L, Jeffrey S, Hanna G, et al.: Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol 2001;75:4999-5008.
6. Antinori A, Zaccarelli M, Cingolani A, et al.: Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure. AIDS Res Hum Retroviruses 2002;18:835-838.
7. Madruga JV, Cahn P, Grinsztejn B, et al.: Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1:24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370:29-38.
8. Lazzarin A, Campbell T, Clotet B, et al.: Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2:24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370:39-48.
9. Katlama C, Haubrich R, Lalezari J, et al.: Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: Pooled week 48 analysis of two randomized, controlled trials. AIDS 2009;23:2289-2300.
10. Trottier B, Mills A, Cahn P, et al.: Durable efficacy and safety of etravirine in treatment-experienced, HIV-1-infected patients: Pooled Week 96 results from the Phase III DUET-1 and DUET-2 trials. 18th Annual Canadian Conference on HIV/AIDS Research, Vancouver, Canada, April 23-26 2009. Abstract P148.
11. Mills A, Cahn P, Molina J-M, et al.: Etravirine demonstrates durable efficacy in treatment-experienced patients in the DUET trials: Pooled 96-week results. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa, July 19-22 2009. Abstract MOPEB036.
12. Campbell T, Grinsztejn B, Hartikainen J, et al.: Long-term safety profile of etravirine in treatment-experienced, HIV-1-infected patients: Pooled 96-week results from the Phase III DUET trials. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa, July 19-22 2009. Abstract MOPEB038.
13. Tibotec Inc. INTELENCE (etravirine). Full prescribing information, August 2009. Available from: http://www.intelence-info.com/intelence/assets/pdf/ INTELENCE-PI.pdf (Accessed 29 September 2009).
14. INTELENCE (etravirine) Summary of Product Characteristics, August 2009. Available from http://www.emea.europa.eu/humandocs/PDFs/EPAR/intelence/emea- combinedh900en.pdf (Accessed 29 September 2009).
15. Vingerhoets J, Tambuyzer L, Azijn H, et al.: Resistance profile of etravirine: Combined analysis of baseline genotypic and phenotypic data from the DUET studies. AIDS 2010;24:503-514.
16. Benhamida J, Chappey C, Coakley E, and Parkin NT: HIV-1 genotype algorithms for prediction of etravirine susceptibility: Novel mutations and weighting factors identified through correlations to phenotype. Antivir Ther 2008;13:A142.
17. The Stanford University HIV Drug Resistance Database. NNRTI resistance notes: NNRTI resistance matrix. Available from http://hivdb.stanford.edu/cgi- bin/NNRTIResiNote.cgi (Updated 10 June 2008; Accessed 12 October 2009).
18. Tambuyzer L, Vingerhoets J, Azijn H, et al.: Comparison of two etravirine weighted genotypic scores with phenotypic susceptibility and virologic response data. 7th European HIV Drug Resistance Workshop, Stockholm, Sweden, March 25-27 2009. Abstract 114.
19. Hertogs K, de Béthune MP, Miller V, et al.: A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 1998;42:269-276.
20. Tambuyzer L, Azijn H, Rimsky LT, et al.: Compilation and prevalence of mutations associated with resistance to nonnucleoside reverse transcriptase inhibitors. Antivir Ther 2009;14:103-109.
21. Johnson VA, Brun-Vézinet F, Clotet B, et al.: Update of the drug resistance mutations in HIV-1: December 2008. Top HIV Med 2008;16:138-145.
22. De Meyer S, Dierynck I, Lathouwers E, et al.: Identification of mutations predictive of a diminished response to darunavir/ritonavir: Analysis of data from treatment-experienced patients in POWER 1, 2, 3 and DUET-1 and DUET-2. 6th European HIV Drug Resistance Workshop, Budapest, Hungary, March 26-28, 2008. Abstract 54.
23. De Meyer S, Vangeneugden T, van Baelen B, et al.: Resistance profile of darunavir: Combined 24-week results from the POWER trials. AIDS Res Hum Retroviruses 2008;24:379-388.
24. Pauwels R, Hertogs K, Kemp S, et al.: Comprehensive HIV drug resistance monitoring using rapid, high-throughput phenotypic and genotypic assays with correlative data analysis. 2nd International Workshop on HIV Drug Resistance, Lake Maggiore, Italy, June 24-27 1998. Abstract 51.
25. Cahn P, Haubrich R, Leider J, et al.: Pooled 24-week results of DUET-1 and DUET-2: TMC125 (etravirine; ETR) versus placebo in 1203 treatment- experienced HIV-1-infected patients. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, USA, September 17-20 2007. Abstract H-717.
26. Xu H, Quan Y, Brenner BG, et al.: Human Immunodeficiency Virus Type 1 rebombinant reverse transcriptase enzymes containing the G190A and Y181C resistance mutations remain sensitive to etravirine. Antimicrob Agents Chemother 2009;53:4667-4672.
27. Marcelin A-G, Flandre P, Descamps D, et al.: Factors associated with early virological response to etravirine in NNRTI-experienced HIV-infected patients. 16th Conference on Retroviruses and Opportunistic Infections, Montréal, Canada, February 8-11 2009. Abstract 645.
28. Azijn H, Tirry I, Vingerhoets J, et al.: TMC278, a next-generation NNRTI, active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother 2010;54:718-727.
29. Hatano H, Hunt P, Weidler J, et al.: Rate of viral evolution and risk of losing future drug options in heavily pretreated, HIV-infected patients who continue to receive a stable, partially suppressive treatment regimen. Clin Infect Dis 2006;43:1329-1336.
30. Cozzi-Lepri A, Phillips NA, Ruiz L, et al.: Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen. AIDS 2007;21:721-732.
31. Hammer SM, Eron JJ Jr, Reiss P, et al.: Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. J American Med Assoc 2008;300:555-570.
32. DHHS Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services. December 1, 2009;1-161. Available at http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf (Accessed 9 December 2009).